[go: up one dir, main page]

CN113508139A - 结合人lag-3的抗体、其制备方法和用途 - Google Patents

结合人lag-3的抗体、其制备方法和用途 Download PDF

Info

Publication number
CN113508139A
CN113508139A CN202080015287.9A CN202080015287A CN113508139A CN 113508139 A CN113508139 A CN 113508139A CN 202080015287 A CN202080015287 A CN 202080015287A CN 113508139 A CN113508139 A CN 113508139A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080015287.9A
Other languages
English (en)
Other versions
CN113508139B (zh
Inventor
赵杰
黄浩旻
朱祯平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of CN113508139A publication Critical patent/CN113508139A/zh
Application granted granted Critical
Publication of CN113508139B publication Critical patent/CN113508139B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了能够特异性结合人LAG‑3的抗体或其抗原结合片段，所述抗体或其抗原结合片段具有增强混合淋巴细胞反应的生物学活性，可用于制备癌症免疫疗法的药物。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN202080015287.9A 2019-02-28 2020-02-20 结合人lag-3的抗体、其制备方法和用途 Active CN113508139B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101489145 2019-02-28
CN201910148914.5A CN111620949A (zh) 2019-02-28 2019-02-28 结合人lag-3的抗体、其制备方法和用途
PCT/CN2020/076023 WO2020173378A1 (zh) 2019-02-28 2020-02-20 结合人lag-3的抗体、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113508139A true CN113508139A (zh) 2021-10-15
CN113508139B CN113508139B (zh) 2022-09-13

Family

ID=72239090

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910148914.5A Pending CN111620949A (zh) 2019-02-28 2019-02-28 结合人lag-3的抗体、其制备方法和用途
CN202080015287.9A Active CN113508139B (zh) 2019-02-28 2020-02-20 结合人lag-3的抗体、其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910148914.5A Pending CN111620949A (zh) 2019-02-28 2019-02-28 结合人lag-3的抗体、其制备方法和用途

Country Status (4)

Country Link
EP (1) EP3932948A4 (zh)
JP (1) JP2022523929A (zh)
CN (2) CN111620949A (zh)
WO (1) WO2020173378A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112759648B (zh) * 2020-09-30 2024-01-16 白先宏 Lag-3结合分子及其应用
CN114456267B (zh) * 2020-11-03 2023-12-01 浙江大学医学院附属第二医院 一种抗cd73人源化单克隆抗体及其应用
CN116514972B (zh) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN115536749A (zh) 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
CN117159703B (zh) * 2023-11-02 2024-04-02 正大天晴(广州)医药有限公司 含抗lag-3抗体的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176921A (zh) * 2008-08-11 2011-09-07 梅达雷克斯股份有限公司 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途
WO2017219995A1 (zh) * 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
WO2019011306A1 (en) * 2017-07-13 2019-01-17 Nanjing Leads Biolabs Co., Ltd. LAG-3 BINDING ANTIBODIES AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP7074341B2 (ja) * 2015-09-02 2022-05-24 イムテップ エス．アー．エス． 抗ｌａｇ－３抗体
TWI773694B (zh) * 2016-10-11 2022-08-11 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
IL265844B2 (en) * 2016-10-13 2024-03-01 Symphogen As Anti-lag-3 antibodies and compositions
CN111050792B (zh) * 2017-08-30 2024-05-31 凡恩世制药(北京)有限公司 抗lag-3抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176921A (zh) * 2008-08-11 2011-09-07 梅达雷克斯股份有限公司 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途
WO2017219995A1 (zh) * 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
WO2019011306A1 (en) * 2017-07-13 2019-01-17 Nanjing Leads Biolabs Co., Ltd. LAG-3 BINDING ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
EP3932948A1 (en) 2022-01-05
CN111620949A (zh) 2020-09-04
WO2020173378A1 (zh) 2020-09-03
JP2022523929A (ja) 2022-04-27
EP3932948A4 (en) 2023-02-15
CN113508139B (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
KR102365972B1 (ko) 항-pd-1 항체 및 이의 용도
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP7215759B2 (ja) ４－１ｂｂ抗体およびその製造方法と使用
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
CN107973854B (zh) Pdl1单克隆抗体及其应用
CN110272490B (zh) 靶向ctla-4抗体、其制备方法和用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN113508139B (zh) 结合人lag-3的抗体、其制备方法和用途
JP2019503687A (ja) 抗ｐｄ−ｌ１抗体およびその使用
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN111065652A (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
EP4458854A1 (en) Gprc5d antibody and application thereof
WO2020038404A1 (zh) 抗人claudin 18.2单克隆抗体及其应用
WO2023025315A1 (zh) 抗b7-h3抗体、其制备方法及用途
CN113004408B (zh) 抗人程序死亡因子-1单克隆抗体
CN114656566A (zh) 一种靶向cd47的抗体及其应用
CN110343178B (zh) 抗人lag-3单克隆抗体及其应用
CN115109157A (zh) 抗体或其抗原结合片段，其制备方法及医药用途
CN114316047B (zh) 一组pd-1单克隆抗体及其医药用途
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052590

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant